Biotech and Pharma Insiders continue buying the Dip

June 06 08:54 2022
Peter Lynch may have said it best when he stated, “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” That’s because, unlike insider buys, which are unscheduled, many insider sales are via Rule 10b5-1 plans, which predetermine the sales schedule to avoid insider influence.

From employing AI trading algorithms to watching somebody yell “buy, buy, buy”, investors are always looking for a leg up. Some even track certain politicians’ trades, but the lag time in identifying those investments usually causes the little guys to miss out on much of the upswing and, in some cases, become the politicians’ de facto exit strategy.

While not perfect, a better system, for most investors, is to follow the SEC Form 4 reports, which tracks reported insider trading. After all, who knows more about a Company’s prospects than the Company’s insiders?

Peter Lynch may have said it best when he stated, “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” That’s because, unlike insider buys, which are unscheduled, many insider sales are via Rule 10b5-1 plans, which predetermine the sales schedule to avoid insider influence.

Of course, this system isn’t foolproof, like when a possible member of a 10% owner group, purchased 490,000 shares of Twitter, Inc. (NYSE: TWTR) at $40.73, worth $19,957,700, on May 13 and a few days later sold the same 490,000 shares at $37.27 for $18,262,300; apparently, trying to figure out Elon’s next move glitches the system.

It goes without stating that insiders, like just about every investor on the planet, invest to make a profit. So they’re looking for value and the biotech-stock selloff, which Bloomberg recently reported “has run so far that many companies are now worth less than the amount of cash they have in the bank”, has created fertile investing space, with biotech insiders being among the most active sectors.

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported that Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, purchased 23,351 shares, bring his total to over 11 million shares.

Emmaus has reported Form 4 activity for 13 consecutive months and, over the past 6 months insiders reported purchasing 295,951 shares in 20 transactions, with no reported sales.

Dr. Niihara recently published a CEO Letter highlighting recent initiatives, including Telehealth support for Endari patients and announcing positive real-world data on Endari®, in preventing acute complications from sickle cell disease and hemolysis in pediatric and adult patients, at the 62nd Annual Meeting of the British Society for Haematology.

Cue Biopharma (NASDAQ: CUE) is another listing that’s only reported insider purchases, over the past 6 months, with 6 purchases totaling 1,069,668 shares, including one of its directors recently adding 205,000 shares, to bring their total shares owned to 940,000 shares.

The clinical-stage biopharmaceutical company is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body. It’s scheduled to present at the Jefferies Healthcare Conference this Friday, June 10, at 1:45-2:10 p.m. EDT, on webcast link: https://wsw.com/webcast/jeff240/cue/1682925

Angion Biomedica Corp (NASDAQ: ANGN) recently filed two SEC Form 4 reports stating that Dr. Jay Venkatesan, the Company’s President and Chief Executive Officer, purchased 82,200 shares in two recent sessions, bringing his total to 1,721,457 shares.

Insiders purchased 1,751,754 in 10 transactions and sold 438,824 shares in 5 transactions, during the last 6 months.

The biopharmaceutical company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and highlights of its recent Q1 2022 report include that it had $73 million in cash and cash equivalents, as of March 31, 2022, which it expects to be sufficient to fund planned operations well into 2023.

“In the first quarter of 2022, we made good progress on our strategic objectives for the year,” stated Dr. Venkatesan. Angion’s stated strategic objectives for 2022 are to develop ANG-3070 for treatment of patients with primary proteinuric kidney diseases (PPKDs), including focal segmental glomerular sclerosis (FSGS) and IgA nephropathy (IgAN), which are the subject of Angion’s JUNIPER Phase 2 trial; to develop ANG-3070 for treatment of patients with idiopathic pulmonary fibrosis (IPF), with a planned IND filing in IPF by the end of 2022; and to nominate a lead compound and initiate IND-enabling studies for one or more of the preclinical rho kinase 2 (ROCK2) or CYP11B2 (aldosterone synthase) inhibitor programs.

Also presenting at the upcoming Jefferies Healthcare Conference will be Sangamo Therapeutics, Inc. (NASDAQ: SGMO) on Thursday, June 9 at 9:00 a.m. EDT. Interested parties are invited to sign up for the webcast link at https://investor.sangamo.com/events/event-details/jefferies-healthcare-conference.

The clinical-stage genomic medicine company filed an SEC Form 4 report, for a director who purchased 5,000 shares last week, bringing their total shares to 48,700. Overall insider activity for the last 6 months is 15 purchases of 605,500 total shares versus 4 sales totaling 236,203 shares.

Humacyte, Inc. (NASDAQ: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, reported that Laura E Niklason, Humacyte’s President, CEO and Director, purchased 10,000 shares, making it 5 insider purchases over the last 6 months totaling 34,525 shares, compared to 2 sales totaling 600,000 shares.

Dale Sander and Heather Prichard, Ph.D., respectively Humacyte’s Chief Financial Officer and Chief Operating Officer, delivered a corporate presentation in-person at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 10:30 a.m. ET. The webcast will be available for replay for at least 30 days following the presentation at https://investors.humacyte.com/news-events/events-and-presentations.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

DISCLAIMER:

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Materials in this release are informational and should never be considered research. You must do your own due diligence by reading all available public information. This release is a corporate public statement, and believed to be reliable. The principle editor of 24/7 has been compensated for the release of this press article by Emmaus. The editor and an affiliate own EMMA shares that were purchased in the open market. The editor and an affiliate also own ANGN shares purchased in the open market. The editor will not be trading in the market and, if that changes within the next 30 days, will update its intention to do so. 24/7 makes no representations and warranties to the completeness of materials provided and are subject to change without notice. 24/7 is not responsible for any gains or losses which result from our opinions or coverage expressed in our emails or our site and readers are cautioned that investing has risks and you may lose all or a portion of your money.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

Media Contact
Company Name: 24/7 Market News
Contact Person: Editor
Email: Send Email
Phone: 720.288.8495
Country: United States
Website: https://www.247marketnews.com/

  Categories: